

Special Issue

Metastatic Gastrointestinal (GI) Cancers

Message from the Guest Editor

The management of gastrointestinal (GI) cancer patients' diagnosis and treatment remains challenging, particularly in solid tumors, due to the variable histo-architecture, the tumor microenvironment, and the metastatic potential. Moreover, the prognosis of GI cancer patients with metastatic disease is extremely grim. We still have very limited options for the management of metastatic GI cancer patients. Among all GI cancers, the diagnosis and treatment of pancreatic cancer has been the most difficult due to excessive desmoplasia, poor infusion of drugs into tumors, and the very high metastatic potential of tumors. This Special Issue aims to shed light on the cellular and molecular mechanisms of different metastatic GI cancers and provide new insights into these oncogenic signaling pathways. This Special Issue also aims to cover the involvement of nanomedicine in the management of cancer patients and potential upcoming nanotechnology platforms that may be useful in the future for cancer treatment, cancer diagnosis, and tumor imaging.

Guest Editor

Prof. Dr. Subhash C. Chauhan

Department of Immunology and Microbiology, South Texas Center of Excellence in Cancer Research, School of Medicine, University of Texas Rio Grande Valley, Biomedical Research Building, 5300 North L Street, Room 1.200, McAllen, TX 78504, USA

Deadline for manuscript submissions

closed (10 August 2021)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/57130

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)